MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Category Archives: Diagnosis & Differentiation

Cytological Profile of a Case of Malignant Mesothelioma of Pleura with Supraclavicular Lymph Node Metastasis

Journal of Cytology 2017 October-December [Link] Priya PV, Deepa S, Jayalakshmy PL Abstract Malignant mesothelioma of pleura is a locally aggressive rare neoplasm of mesothelial cells, which produces distant metastasis in advanced stages of its course. It is exceptional for patients to present with metastasis prior to the detection of primary tumor in the pleura. […]

Comments Off on Cytological Profile of a Case of Malignant Mesothelioma of Pleura with Supraclavicular Lymph Node Metastasis

A link between the fibroblast growth factor axis and the miR-16 family reveals potential new treatment combinations in Mesothelioma

Molecular Oncology 2017 November 1 [Epub ahead of print] [Link] Schelch K, Kirschner MB, Williams M, Cheng YY, van Zandwijk N, Grusch M, Reid G Abstract Malignant pleural mesothelioma (MPM) is an aggressive malignancy with very limited therapeutic options. Fibroblast growth factor (FGF) signals play important roles in mesothelioma cell growth. Several FGFs and FGF […]

Comments Off on A link between the fibroblast growth factor axis and the miR-16 family reveals potential new treatment combinations in Mesothelioma

Cancer antigen profiling for malignant pleural mesothelioma immunotherapy: expression and coexpression of mesothelin, cancer antigen 125, and Wilms tumor 1

Oncotarget 2017 September [Link] Eguchi T, Kadota K, Mayor M, Zauderer MG, Rimner A, Rusch VW, Travis WD, Sadelain M, Adusumilli PS Abstract BACKGROUND: To develop cancer antigen-targeted immunotherapeutic strategies for malignant pleural mesothelioma (MPM), we investigated the individual and coexpressions of the cancer-associated antigens mesothelin (MSLN), cancer antigen 125 (CA125), and Wilms tumor 1 […]

Comments Off on Cancer antigen profiling for malignant pleural mesothelioma immunotherapy: expression and coexpression of mesothelin, cancer antigen 125, and Wilms tumor 1

Targeting microRNA to improve diagnostic and therapeutic approaches for malignant mesothelioma

Oncotarget 2017 August [Link] Birnie KA, PrĂȘle CM, Thompson PJ, Badrian B, Mutsaers S Abstract Malignant mesothelioma is an aggressive and often fatal cancer associated with asbestos exposure. The disease originates in the mesothelial lining of the serosal cavities, most commonly affecting the pleura. Survival rates are low as diagnosis often occurs at an advanced […]

Comments Off on Targeting microRNA to improve diagnostic and therapeutic approaches for malignant mesothelioma

PD-L1 expression associated with worse survival outcome in malignant pleural mesothelioma

Asia-Pacific Journal of Clinical Oncology 2017 November [Epub ahead of print] [Link] Nguyen BH, Montgomery R, Fadia M, Wang J, Ali S Abstract AIM: There is currently a need to identify prognostic biomarkers to assist in a risk adopted approach in treatment of malignant pleural mesothelioma (MPM). Expression of programmed death ligand 1 (PD-L1) has […]

Comments Off on PD-L1 expression associated with worse survival outcome in malignant pleural mesothelioma

Comprehensive pharmacogenomic profiling of malignant pleural mesothelioma identifies a subgroup sensitive to FGFR inhibition

Clinical Cancer Research 2017 October [Epub ahead of print] [Link] Quispel-Janssen JM, Badhai J, Schunselaar L, Price S, Brammeld JS, Iorio F, Kolluri KK, Garnett MJ, Berns A, Baas P, McDermott U, Neefjes J, Alifrangis C Abstract PURPOSE: Despite intense research, treatment options for patients with mesothelioma are limited and offer only modest survival advantage. […]

Comments Off on Comprehensive pharmacogenomic profiling of malignant pleural mesothelioma identifies a subgroup sensitive to FGFR inhibition

Loss of BAP1 Expression in Atypical Mesothelial Proliferations Helps to Predict Malignant Mesothelioma

The American Journal of Surgical Pathology 2017 October [Epub ahead of print] [Link] Pillappa R, Maleszewski JJ, Sukov WR, Bedroske PP, Greipp PT, Boland JM, Yi ES, Peikert T, Aubry MC, Roden AC Abstract Distinguishing reactive mesothelial proliferation from malignant mesothelioma (MM) can be difficult, particularly on small biopsies. In this scenario, a diagnosis of […]

Comments Off on Loss of BAP1 Expression in Atypical Mesothelial Proliferations Helps to Predict Malignant Mesothelioma

Molecular and Histopathological Characterization of the Tumor Immune Microenvironment in Advanced Stage of Malignant Pleural Mesothelioma

Journal of Thoracic Oncology 2017 October [Epub ahead of print] [Link] Patil NS, Righi L, Koeppen H, Zou W, Izzo S, Grosso F, Libener R, Loiacono M, Monica V, Buttigliero C, Novello S, Hegde PS, Papotti M, Kowanetz M, Scagliotti GV Abstract INTRODUCTION: Malignant pleural mesothelioma (MPM) is a rare, highly aggressive, relatively chemo- and […]

Comments Off on Molecular and Histopathological Characterization of the Tumor Immune Microenvironment in Advanced Stage of Malignant Pleural Mesothelioma

Loss of BRCA associated protein 1 expression in malignant mesothelioma and its diagnostic application

Chinese Journal of Pathology 2017 October [Link] Guo ZY, Sun WY, Michele Y, Zhang JL, Hu D, Su HN, Yang WM, Mao W Abstract Objective: To investigate the expression of BRCA-associated protein 1 (BAP1) in malignant mesothelioma, non-small cell lung cancer and carcinosarcoma, and its application in the differential diagnosis. Methods: Twenty-two cases of malignant […]

Comments Off on Loss of BRCA associated protein 1 expression in malignant mesothelioma and its diagnostic application

Targeting mesothelin receptors with drug-loaded bacterial nanocells suppresses human mesothelioma tumour growth in mouse xenograft models

PLoS One 2017 October [Link] Alfaleh MA, Howard CB, Sedliarou I, Jones ML, Gudhka R, Vanegas N, Weiss J, Suurbach JH, de Bakker CJ, Milne MR, Rumballe BA, MacDiarmid JA, Brahmbhatt H, Mahler SM Abstract Human malignant mesothelioma is a chemoresistant tumour that develops from mesothelial cells, commonly associated with asbestos exposure. Malignant mesothelioma incidence […]

Comments Off on Targeting mesothelin receptors with drug-loaded bacterial nanocells suppresses human mesothelioma tumour growth in mouse xenograft models